Hologic (HOLX) closed the most recent trading day at $56.94, moving -1.08% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.36%. Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%.
The medical device maker's stock has dropped by 6.36% in the past month, exceeding the Medical sector's loss of 9.83% and lagging the S&P 500's loss of 5.6%.
Investors will be eagerly watching for the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 1, 2025. On that day, Hologic is projected to report earnings of $1.02 per share, which would represent a year-over-year decline of 0.97%. At the same time, our most recent consensus estimate is projecting a revenue of $1 billion, reflecting a 1.56% fall from the equivalent quarter last year.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.27 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +4.66% and +1.29%, respectively.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Hologic. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. Hologic is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Hologic's current valuation metrics, including its Forward P/E ratio of 13.48. This expresses a discount compared to the average Forward P/E of 23.64 of its industry.
Meanwhile, HOLX's PEG ratio is currently 1.97. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical - Instruments industry had an average PEG ratio of 2.12.
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 60, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
